Summary
AbbVie Inc. reported strong financial results for the second quarter and first half of 2016, driven by robust revenue growth primarily from its key drug HUMIRA, which continues to show significant year-over-year increases. The company also saw substantial contributions from IMBRUVICA, reflecting successful integration post-acquisition. Strategic acquisitions, notably of Stemcentrx in June 2016 and earlier of Pharmacyclics, are enhancing AbbVie's pipeline, particularly in oncology, though they also contributed to increased operating costs and interest expenses due to associated debt financing. Despite increased R&D spending and the costs associated with recent acquisitions, AbbVie demonstrated improved operating margins and strong cash flow generation. The company also continued its commitment to returning capital to shareholders through dividends and share repurchases, including a new accelerated share repurchase agreement following the Stemcentrx acquisition. Management remains focused on innovation-driven growth, pipeline advancement, and strategic partnerships to address complex diseases.
Financial Highlights
53 data points| Revenue | $6.45B |
| Cost of Revenue | $1.41B |
| Gross Profit | $5.05B |
| SG&A Expenses | $1.47B |
| Operating Expenses | $4.07B |
| Operating Income | $2.39B |
| Interest Expense | $245.00M |
| Net Income | $1.61B |
| EPS (Basic) | $0.99 |
| EPS (Diluted) | $0.98 |
| Shares Outstanding (Basic) | 1.62B |
| Shares Outstanding (Diluted) | 1.63B |
Key Highlights
- 1AbbVie reported an 18% increase in net revenues for both the three and six months ended June 30, 2016, reaching $6.45 billion and $12.41 billion, respectively.
- 2HUMIRA sales showed strong performance, increasing 17% year-over-year for the three months to $4.15 billion and 16% for the six months to $7.73 billion.
- 3The acquisition of Stemcentrx was completed on June 1, 2016, for $6.2 billion, significantly expanding AbbVie's oncology pipeline with assets like Rova-T.
- 4Net earnings for the three months ended June 30, 2016, were $1.61 billion ($0.98 per diluted share), up from $1.37 billion ($0.83 per diluted share) in the prior year.
- 5Operating earnings increased significantly to $2.39 billion for the quarter and $4.67 billion for the six months, up from $1.85 billion and $3.54 billion in the respective prior year periods.
- 6The company generated $4.05 billion in cash flow from operating activities for the first six months of 2016, an increase from $3.42 billion in the prior year.
- 7AbbVie issued $7.8 billion in senior notes in May 2016 to finance acquisitions and repay debt, contributing to an increase in interest expense.